# Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer

> **NCT00976677** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 10 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** paclitaxel
- **DRUG:** carboplatin
- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT00976677
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2012-07
- **Final completion:** 2013-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2014-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00976677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00976677, "Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00976677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*